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Nitric oxide (NO) donors produce NO-related activity when applied to biological systems. Among its diverse functions, NO has
been implicated in vascular smooth muscle relaxation. Despite the great importance of NO in biological systems, its
pharmacological and physiological studies have been limited due to its high reactivity and short half-life. In this review we will
focus on our recent investigations of nitrosyl ruthenium complexes as NO-delivery agents and their effects on vascular smooth
muscle cell relaxation. The high affinity of ruthenium for NO is a marked feature of its chemistry. The main signaling pathway
responsible for the vascular relaxation induced by NO involves the activation of soluble guanylyl-cyclase, with subsequent
accumulation of cGMP and activation of cGMP-dependent protein kinase. This in turn can activate several proteins such as K+
channels as well as induce vasodilatation by a decrease in cytosolic Ca2+. Oxidative stress and associated oxidative damage are
mediators of vascular damage in several cardiovascular diseases, including hypertension. The increased production of the
superoxide anion (O2-) by the vascular wall has been observed in different animal models of hypertension. Vascular relaxation
to the endogenous NO-related response or to NO released from NO deliverers is impaired in vessels from renal hypertensive
(2K-1C) rats. A growing amount of evidence supports the possibility that increased NO inactivation by excess O2- may account
for the decreased NO bioavailability and vascular dysfunction in hypertension.
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Introduction
Endothelium dysfunction that leads to nitric oxide (NO)
deficiency is present in several cardiovascular diseases
(1). The discovery that NO is involved in multiple physi-
ological and pathophysiological processes has promoted
a large amount of pharmacological research into the de-
sign of new drugs that are capable of influencing NO
production, directly and/or indirectly, for therapeutic pur-
poses. In particular, the so-called NO donor drugs could
have an important therapeutic effect on the treatment of
many cardiovascular diseases such as angina and hyper-
tension. The classic nitrovasodilators organic nitrate and
nitrite esters, including nitroglycerin, amyl nitrite, isosor-
bide dinitrate, isosorbide 5-mononitrate and nicorandil,
have been used in the treatment of cardiovascular dis-
eases for many years (2).
NO donors produce NO-related activity when applied
to biological systems, so they are mainly suited to either
mimic an endogenous NO-related response or substitute
an endogenous NO deficiency (1). NO is also the pharma-
cological principle of a number of drugs collectively termed
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nitrovasodilators, which are clinically used to control hy-
pertensive crisis, protect patients from attacks of angina
pectoris, and unload the heart during acute heart failure.
Numerous other compounds, including NONOates, are
available for the experimental generation of NO (3,4).
Several NO donors have been used in clinical settings for
decades (e.g., nitroglycerin and sodium nitroprusside).
However, the growing interest in NO physiology since the
mid 1980’s has led to the development of a variety of new
NO donors that offer several advantages over conven-
tional NO donors (1,5). Recently, several new metal com-
plexes have been studied as NO donors or scavengers,
including nitrosyl ruthenium complexes, nitrite complexes
and related species (6-17).
The chemistry of metal nitrosyl complexes has taken
on added significance in recent years because of the
important role involving transition metal in the biological
process of NO, as well as the possibility of producing
thermodynamically stable and kinetically labile species
(18-20). Such strategies have focused on the development
of pharmacological substances capable of releasing NO at
specific rates in tissues, in order to overcome NO defi-
ciency. NO scavengers that reduce NO levels where ex-
cessive production is observed have also been designed.
In recent years, there has been increasing interest in the
chemistry of ruthenium complexes and their suitability as
potential pharmaceutical agents because of their usually
low cytotoxic characteristics (10,21). Ruthenium (II) and
ruthenium (III) are the most commonly employed ions and
they are generally surrounded by six coordination spheres.
The high affinity of ruthenium for NO is a marked
feature of its chemistry. Because this system has proven to
be an NO donor agent under external stimulation, a large
number of ruthenium complexes are currently being inves-
tigated. Compared with the existing NO-donor drugs, this
system has the advantage that NO could be released at a
specific biological target. Although several nitrosyl ruthe-
nium complexes have been synthesized and their chemi-
cal and physicochemical properties have been described,
only few examples involve the above-discussed pharma-
cological aspects. In the present report, we will focus our
attention on the compounds shown in Figure 1. A strategy
that we have adopted in the design of nitrosyl ruthenium
complexes is to bind ruthenium (II) with ligands that confer
high thermodynamic stability and also water solubility to
the resulting complex.
The co-ligands (L) in Figure 1 are named 1,4,8,12-
tetraazacyclopentadecane ([15]aneN4) (I); 2,2'-bipyridine
(bpy) (II) and 1,2-benzoquinonediimine-5-carboxylate (bdqi-
COO) (III). Species (I) and (III) are characterized by a {RuII-
NO+}3+ bond, while compound (II) consists of {RuII-NO0}2+.
All the species are stable at physiological pH, although at
pH ≥9.0 equilibrium with an appreciable amount of nitrite
bound to ruthenium (II) takes place, as depicted in Equa-
tion 1.
[RuL5NO]3+ + 2OH- ↔ [RuL5(NO)2]+ + H2O (Equation 1)
Compounds (I) and (III) produce NO under light irradia-
tion (Equation 2) or reducing medium (Equation 3) while
compound (II) is an NO donor only under light stimulation.
[RuL5NO]3+ hν → [RuL5(H2O)]3+ + NO                (Equation 2)
[RuL5NO]3+ + e- → [RuL5(H2O)]2+ + NO                (Equation 3)
On the basis of these properties, we have performed a
series of pharmacological assays with these nitrosyl ruthe-
Figure 1. Molecular structure of cis-[Ru(bpy)2Cl(NO)]+, trans-[RuCl([15]aneN4)NO]2+ and [Ru(terpy)(bdq-COO)NO]3+ (silver =
ruthenium, dark blue = nitrogen, light blue = carbon, and red = oxygen; hydrogen atoms have been omitted in the structure).
cis-[Ru(bpy)2CI(NO)]+ trans-[RuCI([15]aneN4)NO]2+ [Ru(terpy)(bdq-COO)NO]3+
89
Braz J Med Biol Res 42(1) 2009
NO donors and vasodilatation
www.bjournal.com.br
nium complexes as new NO donor species. Our results
suggest a new class of metal-based drugs.
Nitrosyl ruthenium complex is an NO donor
that induces rat aorta relaxation
The mechanism by which NO induces relaxation is the
subject of much investigation. When the signaling mole-
cule NO enters a vascular smooth muscle cell, it activates
an enzyme called guanylyl cyclase, which produces the
second messenger 3’5’guanosine-monophosphate (cGMP)
(22,23). Guanylyl cyclase is a heterodimer that consists of
two subunits, termed α and β, which are linked by disulfide
bonds, and it has a prosthetic heme group covalently
bound to the heterodimer (23,24). NO activates cGMP
synthesis by binding to the heme group, leading to the
conversion of guanosine triphosphate to cGMP. cGMP
activates a serine/threonine kinase, the cGMP-dependent
protein kinase G (PKG), leading to the phosphorylation of
key regulatory proteins (25). PKG activation has been
associated with isoform-specific autophosphorylation,
which results in changes in the properties of the enzyme,
including increased sensitivity to cyclic nucleotides and
increased constitutive activity (26,27). An increase in cel-
lular cGMP levels occurs in response to the activation of
the membrane guanylyl-cyclase or more commonly by
activation of soluble guanylyl-cyclase by NO (28). Numer-
ous studies have inferred activation of PKG in response to
diverse ligands, presumably downstream of NO produc-
tion (29). NO has two signaling pathways, a cGMP-de-
pendent one and a cGMP independent one, which could
directly activate K+ channels (30).
Potassium channel
Potassium channels are a group of transmembrane
proteins that have several functions (31,32). The activa-
tion of K+ channels in the vascular smooth muscle cell
membrane stimulates K+ efflux, membrane hyperpolariza-
tion, decreased Ca2+ entry through voltage-operated chan-
nels, and vasodilatation. Changes in the activity of the K+
channels regulate the vascular tone.
The main K+ channel subtypes consist of large and
small conductance Ca2+-activated K+ channels (BKCa),
which are selectively blocked by iberiotoxin and apamin,
respectively. The K+ channel group that appears to be
involved in vascular tone regulation also includes ATP-
sensitive potassium channels, which are blocked by gli-
benclamide voltage-dependent channels (KV), which in
turn are blocked by 4-aminopyridine and inward rectifier
channels. The expression of these channels has been
reported to vary among vessels of different sizes and
vascular beds (33). However, the presence of KV and BKCa
channels has been demonstrated in all the vascular myo-
cytes tested (34).
Altered function of K+ channels is associated with hy-
pertension, and KV and BKCa are the most often studied
channels involved in the vascular tone regulation. Increased
vascular tone, a typical feature of most forms of hyperten-
sion, has been associated with impaired NO signaling.
Although the main mechanism of vasodilatation induced
by the ruthenium-derived NO donors is due to K+ channel
activation and membrane hyperpolarization in normoten-
sive rat aorta, we have reported that none of the K+ channel
subtypes are activated by the NO donor trans-[RuCl([15]
aneN4)NO]2+ in the aorta from renal hypertensive rats (35).
These results demonstrate that in this model of hyperten-
sion, impaired K+ channels can contribute to decreased
vasodilatation in response to NO.
Vascular relaxation induced by the NO donors
The new NO donors like trans-[RuCl([15]aneN4)NO]2+
(15-ane), [Ru(NH.NHq) (terpy)NO+]3+ (TERPY), cis-[RuCl
(bpy)(2)(NO)](PF(6)) (RUNOCL), and sodium nitroprus-
side (SNP) induce relaxation in a concentration-depend-
ent manner in denuded aortic rings pre-contracted with
norepinephrine (6,7). An illustration of this effect can be
seen in Figure 2, which demonstrates the similar concen-
tration dependent for all the new NO donors.
Figure 2. Effects of trans-[RuCl([15]aneN4)NO]2+ and sodium
nitroprusside (SNP) on rat thoracic aorta pre-contracted with
norepinephrine. The arteries were pre-contracted with 0.1 μM
norepinephrine and trans-[RuCl([15]aneN4)NO]2+ (open
squares, N = 6) or SNP (filled squares, N = 6) was cumulatively
added (0.1 nM to 100 μM and 0.1 nM to 0.3 μM, respectively).
Data are reported as means ± SEM of N experiments performed
on preparations obtained from different animals. From Ref. 36
(with permission).
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NO released from all the NO donors is the common
mediator that elicits their vasodilatory effects. The activa-
tion of guanylyl cyclase and accumulated cGMP lowers
cytosolic Ca2+, leading to vasodilatation. Regarding the
vascular relaxation induced by these new NO donors, all
the new NO compounds induce vascular relaxation in a
concentration-dependent way in denuded rat aortas pre-
contracted with 0.1 μmol/L phenylephrine. The specificity
of soluble guanyl cyclase activation should be different for
the different NO donors. NO can exist in a variety of forms
such as free radical and nitrosyl or nitronium ions, and its
form depends on the NO source. Therefore, the NO re-
leased from NO donors can differ from the NO produced in
endothelial cells. This could explain the differences in
potency and efficacy of the known NO donors in inducing
vasodilatation. The NO donor SNP also induces concen-
tration-dependent relaxation, but it is more potent (pD2:
7.97 ± 0.07, N = 6) than 15-ane (pD2: 5.03 ± 0.2, N = 6),
TERPY (pD2: 6.47 ± 0.13, N = 6) and RUNOCL (pD2: 6.62
± 0.16, N = 7). In relation to the maximum relaxant effect,
however, all the compounds induce a similar effect, as
shown by Emax (105.86 ± 3.34%, N = 6 for SNP; 98.35 ±
1.22%, N = 6 for 15-ane; 102.38 ± 0.38%, N = 6 for TERPY,
and 101.2 ± 3.7%, N = 7 for RUNOCL). When mouse aorta
relaxation is concerned, NO gas, spermine NONOate and
Angeli’s Salt are equipotent, with pD2 in the range of 6.0. All
these new NO donors display an important ability to induce
vascular relaxation (36-40). The potency and efficacy of
these NO donors and those of the authentic NO gas are
comparable.
Time-course of the relaxation induced by
15-ane, TERPY, RUNOCL, and SNP
The time to reach the maximum relaxation has been
evaluated for the new NO donors. Table 1 shows the
values obtained in denuded aortic rings from normoten-
sive rats. According to the structure and the particular
characteristics of each new NO donor such as extra/
intracellular release (6,35-40), reduction potential (32),
and light activation (6), the time course of the maximum
relaxation can be modulated to a fast/slow event.
Calcium measurements
NO is an important regulator of vascular smooth muscle
relaxation. It is well known that changes in the cytosolic
calcium concentration ([Ca2+]c) play a critical role in the
relaxation of vascular smooth muscle cells (41). When
activated by its second messenger cGMP, PKG modulates
cellular function via phosphorylation of substrate proteins
(42).
It has been shown that the mechanism of NO-depend-
ent relaxation of the vascular smooth muscle cells involves
a decrease in [Ca2+]c by inhibition of Ca2+ entry (43). It has
also been postulated that NO and cGMP may relax vascu-
lar smooth muscle cells by a cGMP-dependent K+ channel
activation (44). In the same way, a novel mechanism that
operates by a direct effect of NO on Ca2+-dependent K+
channels (45) and L-type calcium current (44) and does
not require cGMP has been demonstrated.
Studies on other types of smooth muscle preparations
indicate that NO/cGMP may decrease [Ca2+]c and reduce
the sensitivity of contractile proteins to Ca2+, thereby re-
sulting in the relaxation of smooth muscle.
Our confocal microscopy studies have shown that NO
donors like 15-ane, TERPY and RUNOCL decrease [Ca2+]c
in the vascular smooth muscle cells. We have observed a
decrease in [Ca2+]c measured as fluorescence intensity of
the Ca2+ sensitive dye Fluo-3AM after addition of the NO
donors 15-ane (%ΔFI: 14.1 ± 3.5%, N = 4), TERPY (%ΔFI:
55.7 ± 4.8%, N = 5), RUNOCL (%ΔFI: 40.0 ± 10.0%), and
SNP (%ΔFI: 18.6 ± 4.7%, N = 4) (6,7,35). Among these
new NO donors, TERPY leads to a more effective [Ca2+]c
reduction (Figure 3) (6,40,46-49).
Superoxide can contribute to reduced NO
bioavailability and vascular relaxation in renal
hypertensive rats
It is well recognized that reactive oxygen species (ROS)
play an important role in hypertension and in other cardio-
vascular diseases. Vascular cell types such as endothelial
and vascular smooth muscle cells can produce ROS via
cell membrane-associated NAD(P)H oxidase. ROS in-
clude superoxide (O2-), hydrogen peroxide and hydroxyl
anion. Reactive nitrogen species such as NO and peroxy-
nitrite are also biologically important O2 derivatives.
We have reported that relaxation induced by NO re-
Table 1. Time to reach maximum relaxation of aorta ring induced
by nitric oxide (NO) donors (modified Krebs solution, 37°C, [NO
donors] = 0.1 mmol/L).





TERPY = [Ru(NH.NHq) (terpy)NO+]3+; 15-ane = trans-
[RuCl([15]aneN4)NO]2+; RUNOCL = cis-[RuCl(bpy)(2)(NO)]
(PF(6)).
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Figure 3. Decrease in cytosolic Ca2+ concentration ([Ca2+]c) induced by [Ru(NH.NHq)(terpy)NO+]3+ (TERPY) in vascular smooth
muscle cells from rat aortas. Cells were preloaded with Fluo-3AM (10 μM) and stimulated with TERPY (10 μM). Temporal effect of
TERPY in a single vascular smooth muscle cell was recorded with a confocal microscope. TERPY was added after 115 s. The
intensity of the colors indicate higher [Ca2+]c (as shown in the left bar). From Ref. 49 (with permission).
leased from the complexes TERPY and 15-ane is impaired
in the aortic rings from 2K-1C rats. This impairment has
been attributed to increased ROS production. The im-
paired relaxation to TERPY in 2K-1C aortic rings is normal-
ized in the presence of the antioxidant agent vitamin C.
According to Oliveira-Sales et al. (50) the overactivity of
NAD(P)H oxidase-derived ROS and lowered activity of
CuZnSOD, an endogenous antioxidant, could contribute
to 2K-1C hypertension. These investigators have hypoth-
esized that the increased angiotensin II characteristic of
this hypertension model would activate NAD(P)H oxidase.
An imbalance between ROS production and the antioxi-
dant levels could lead to a significant increase in oxidative
stress and hypertension.
We have shown that the basal cytosolic NO concentra-
tion ([NO]c) is lower in 2K-1C than in normotensive (2K)
aortic rings (49). After stimulation with the NO donor TERPY,
[NO]c is also lower in 2K compared with 2K-1C aortic rings.
These results indicate that NO bioavailability under basal
conditions or bioavailability of NO released from TERPY is
larger in the normotensive than in the renal hypertensive
rat aorta.
Concluding remarks
NO released from the ruthenium complexes induces
vascular smooth muscle relaxation via activation of cGMP
production and K+ channel activation in normotensive rat
aorta, as well as decreased cytosolic Ca2+ concentrations.
Vascular smooth muscle relaxation induced by the new
NO donors is impaired in renal hypertensive rat aortas due
to vascular dysfunction by decreased NO bioavailability
and impaired K+ channel activation.
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